Thrombolysis with alteplase 3-4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study

The Lancet

Volumn 372, Issue 9646, 2008, Pages 1303-1309

  Wahlgren, Nils ^a   Ahmed, Niaz ^a   Dávalos, Antoni ^b   Hacke, Werner ^c   Millán, Mónica ^b   Muir, Keith ^d   Roine, Risto O ^e   Toni, Danilo ^f   Lees, Kennedy R ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ACUTE DISEASE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; FEMALE; HUMAN; INDEPENDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SAFETY; PRIORITY JOURNAL; RANKIN SCALE;

EID: 53249095475     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61339-2     Document Type: Article

References (20)

1. Wahlgren N., Ahmed N., Dávalos A., et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369 (2007) 275-282
2. Wahlgren N, Ahmed N, Eriksson N, et al: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST): multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials. Stroke 2008 (in press).
3. Hacke W., Donnan G., Fieschi C., et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363 (2004) 768-774
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
5. Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274 (1995) 1017-1025
6. Hacke W., Kaste M., Fieschi C., et al., for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352 (1998) 1245-1251
7. Clark W.M., Wissman S., Albers G.W., Jhamandas J.H., Madden K.P., and Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282 (1999) 2019-2026
8. Clark W.M., Albers G.W., Madden K.P., and Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 31 (2000) 811-816
9. SITS-ISTR (Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Register). http://www.acutestroke.org (accessed Aug 8, 2008).
10. European Stroke Organisation (ESO) Executive Committee. ESO Writing Committee: guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25 (2008) 457-507
11. Adams H.P., del Zoppo G., Albert M.J., et al. Guidelines for the early management of adults with ischemic stroke. Stroke 38 (2007) 1655-1711
12. Brott T., Adams H., and Olinger C. Measurements of acute cerebral infarction, a clinical examination scale. Stroke 20 (1989) 864-870
13. Wardlaw J.M., Sandercock P.A., and Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 34 (2003) 1437-1442
14. Larrue V., von Kummer R.R., Muller A., Bluhmki E., et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32 (2001) 438-441
15. van Swieten J.C., Koudstaal P.J., Visser M.C., et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19 (1988) 604-607
16. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 17 (1998) 857-872
17. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Stroke 24 (1993) 35-41
18. Hacke W, Kaste M, Bluhmki E, for the European Cooperative Acute Stroke Study (ECASS) investigators. Alteplase compared with placebo within 3 to 4·5 hours for acute ischemic stroke. N Engl J Med (in press).
19. Uyttenboogaart M., Vroomen P.C., Stewart R.E., De Keyser J., and Luijckx G.J. Safety of routine IV thrombolysis between 3 and 4·5 h after ischemic stroke. J Neurol Sci 254 (2007) 28-32
20. Schellinger P.D., Thomalla G., Fiehler J., et al. MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients. Stroke 38 (2007) 2640-2645